Clinical trials: Patient With Colorectal Cancer
Colorectal Neoplasms
Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer
RATIONALE: Surgical resection and adjuvant therapy has become the main treatment for resectable colorectal cancer. Treatment with current strategies, however,recurrent rate is high for stage IIIC or R0 resected stage IV.
- Trial name
- CAMCO (NCT01880658)
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Cancer Cachexia, Side Effects
The Effects of n-3 LCPUFAs in Patients With Colorectal Cancer
The aim of this study is to determine the effects of n-3 PUFAs on weight, physical funktion and quality of life in patients with colorectal cancer.
- Conditions
- Cancer Cachexia, Side Effects, Quality of Life
- Trial name
- NCT04699760
- Testing
- Fish Oil
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Copenhagen
Colorectal Cancer
Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining radiation therapy and surgery…
- Trial name
- NCT00002523
- Testing
- fluorouracil, leucovorin calcium, conventional surgery
- Where
- 35 sites in Belgium, France and 8 more
- Volunteers
- 1,011 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer
A Mobile Aplication for the Promotion of Healthy Lifestyle Habits in Patients With Colorectal Cancer
The purpose of this randomized study is to assess the efficacy of a mobile application for the promotion of healthy lifestyle habits (diet and exercise) in colorectal cancer survivors (CCR).
- Trial name
- NCT02837159
- Testing
- mHealth application
- Where
- Spain
- Sponsor
- Universidad de Granada
Colorectal Cancer
Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan
This study is being performed to test if the use of high dose of cetuximab in combination with irinotecan overcomes the resistance seen with standard dose of cetuximab plus irinotecan in patients with wild type KRS tumors that…
- Trial name
- NCT01004159
- Testing
- cetuximab with irinotecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer
- Trial name
- GEN206 (NCT00677924)
- Testing
- Zalutumumab
- Where
- 3 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- Genmab
Colorectal Cancer
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004042
- Testing
- monoclonal antibody F19, iodine I 131 monoclonal antibody F19
- Where
- 3 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer of the Rectum
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
National, multi-center, open-label,randomized, 2-arm phase III superiority trial, comparing neoadjuvant chemotherapy (CT) with mFolfirinox followed by preoperative chemoradiotherapy (CRT), versus preoperative CRT in patients with…
- Trial name
- Néofirinox (NCT01804790)
- Testing
- mFolfirinox, Radiotherapy 50 Gy, Capecitabine
- Where
- 36 sites in France
- Volunteers
- 461 people
- Sponsor
- UNICANCER
Peritoneal Malignancy, Ovarian Cancer
Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy
People who are diagnosed with cancer of the colon/rectum/appendix/ovaries that spreads into the lining of the tummy and some ovarian cancers or people with pseudomyxoma peritonei can often undergo intensive treatment including…
- Conditions
- Peritoneal Malignancy, Ovarian Cancer, Rectum Cancer, Appendix Cancer
- Trial name
- PANO (NCT05305820)
- Testing
- Exercise, Nutrition
- Where
- 3 sites in Ireland
- Volunteers
- 36 people
- Sponsor
- Dublin City University
MSI, dMMR Colorectal Cancer
Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
MSI is a molecular indicator of defective DNA mismatch repair (dMMR). The MSI/dMMR status is observed in all tumor types, representing notably 5% of metastatic colorectal cancers (mCRC), 25% of advanced endometrial cancer and 8%…
- Trial name
- MONAMI (NCT06152523)
- Testing
- Monalizumab/MEDI5257
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Neoplasms, Colonic Neoplasms
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose…
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00056446
- Testing
- Vatalanib
- Where
- 251 sites in United States, Australia and 16 more
- Volunteers
- 855 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Colorectal Cancer
PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
The purpose of this study is to determine the treatment effect of panitumumab in combination with FOLFOX compared to FOLFOX alone as first line therapy for metastatic colorectal cancer
- Trial name
- NCT00364013
- Testing
- Panitumumab, FOLFOX regimen
- Volunteers
- 1,183 people
- Sponsor
- Amgen
Advanced Colorectal Cancer
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 in advanced colorectal cancer subjects.
- Trial name
- NCT06199973
- Testing
- SHR-A1811, TAS-102, Regorafenib , Fruquintinib
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Chronic Limb-Threatening Ischemia, Colorectal Carcinoma
Comparison of Outcomes of Patients With Stage IV Chronic Limb-threatening Ischemia and Colorectal Cancer
Colorectal cancer (CRC) and chronic limb-threatening ischemia (CLTI) are relatively frequent and potentially fatal diseases. However, studies that are comparing clinical outcomes between CRC and CLTI patients in more advanced…
- Conditions
- Chronic Limb-Threatening Ischemia, Colorectal Carcinoma, Colorectal Carcinoma Metastatic in the Liver
- Trial name
- NCT05116696
- Testing
- For chronic limb-threatening ischemia (CLTI) patients revascularisation surgery; for colorectal liver metastasis (CRLM) patients metastatic liver surgery
- Where
- Serbia
- Volunteers
- 836 people
- Sponsor
- Clinical Centre of Serbia
Metastatic Colorectal Cancer
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
This is a phase II trial to examine the efficacy of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (all RAS/NRAS/BRAF/PIK3CA wild-type), metastatic colorectal cancer based on HER2…
- Trial name
- NCT03457896
- Testing
- Trastuzumab, Cetuximab, Neratinib
- Where
- 48 sites in United States
- Volunteers
- 35 people
- Sponsor
- NSABP Foundation Inc
Colon Cancer
Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer
This is a retrospective genetic analysis of stored tumor tissue samples to evaluate the distribution of Recurrence Score® and gene groups of stage II colon cancer in African American (AA) and Caucasian individuals.
- Trial name
- NCT01479894
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Arkansas
Colorectal Cancer, Metastatic
Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6
The purpose of this study is to compare OnDose® based pharmacokinetic administration of 5-FU versus standard Body Surface Area (BSA) based administration of 5-FU in patients with metastatic colorectal cancer treated with…
- Trial name
- PROFUSE (NCT01468623)
- Testing
- Pharmacokinetic 5-FU dose adjustment using OnDose® assay, Standard of care
- Where
- 58 sites in United States
- Volunteers
- 51 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Colorectal Cancer, Esophageal Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer
RATIONALE: LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced pancreatic, esophageal, stomach, colon or rectal cancer.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00010270
- Testing
- LMB-9 immunotoxin
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Freiburg
Solid Tumor
KN035 for dMMR/MSI-H Advanced Solid Tumors
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with…
- Trial name
- NCT03667170
- Testing
- KN035
- Where
- 27 sites in China
- Volunteers
- 188 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Colonic Neoplasms
Utility Of Citogenex Administration In Patients With Colon-Rectal Cancer
The main aim of the present study is to test the efficacy and safety of CITOGENEX administration in patients with colon-rectal cancer.
- Trial name
- CITOGENEX PA (NCT01477866)
- Testing
- citogenex, conventional therapy
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- University of Palermo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.